about
The Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityPharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicitySingle base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression.Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates.Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy.Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.Genetic variation in the human cytochrome P450 supergene family.Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities.Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation.How to Consider Rare Genetic Variants in Personalized Drug Therapy.Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multi-center study.Modulation of Phase Shift between Wnt and Notch Signaling Oscillations Controls Mesoderm Segmentation.Integrating rare genetic variants into pharmacogenetic drug response predictions.Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.Calcium Signaling in Liver Injury and RegenerationHuman liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactionsTranslating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutionsGenetic variability and population diversity of the human SLCO (OATP) transporter familyHuman hepatic 3D spheroids as a model for steatosis and insulin resistanceGlobal genetic diversity of human apolipoproteins and effects on cardiovascular disease riskPrecision Medicine and Rare Genetic VariantsDysregulation of miR-223 constitutes a promising biomarker that informs about clinical outcomes of acute liver failureComprehensive overview of the pharmacogenetic diversity in Ashkenazi JewsGermline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patientsIn Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1)Liver macrophages inhibit the endogenous antioxidant response in obesity-associated insulin resistanceOrganotypic and Microphysiological Models of Liver, Gut, and Kidney for Studies of Drug Metabolism, Pharmacokinetics, and ToxicityFunctional characterization of CYP2D7 gene variantsEmerging strategies to bridge the gap between pharmacogenomic research and its clinical implementationCYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinomaEthnogeographic and inter-individual variability of human ABC transportersCurrent Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical AssaysThe genetic landscape of the human solute carrier (SLC) transporter superfamilyPrediction of drug response and adverse drug reactions: From twin studies to Next Generation SequencingAn optimized prediction framework to assess the functional impact of pharmacogenetic variants
P50
Q28080256-894F8932-C852-408B-A982-BF3B709ACBD9Q35812195-D8E0FD0C-34A2-4EC6-9FE7-10A503CEA358Q36061736-66AD8B62-BD53-4600-AA0C-F637375C82C6Q37210958-1F16CA53-FE6E-4B8C-B5A6-E932C4C97EA3Q37718523-5BDEA078-600E-4C3A-845C-B5B6D685C2E6Q38818407-97D1FB10-E6E2-4EAF-863F-68CA84FC73CDQ38853651-E673D23B-4C73-4A80-8531-37D36C0AA292Q39380936-D09E51E1-73C8-40B3-B624-591374ED30DEQ39833609-011655D5-2D2C-4915-8C3C-EE1F5AB2BC80Q40573406-F2A78DA5-55F8-4F42-A1C3-3E5D40CD2A6FQ40770241-12F0D4C7-C1EF-4AE8-8C9F-BF7838DCB4F0Q47357309-CEFA6368-EAB9-461B-8E98-EB4DA7878CDDQ47656091-D1805339-E689-4015-B74D-F875731C2BE9Q48287152-D15D1BCE-8ECA-4F9E-995C-64A65BB55542Q48289656-AD6DD766-38A7-41D2-91DF-80ABD45305CAQ50062827-990D4008-2010-4040-9C60-47A2DB0F3F8DQ50422140-0D75B0D6-F1BD-42B0-B7D0-407F02AB8230Q54940794-B77BB07B-3616-4025-965A-B5BC5215DBA3Q55315206-EEAE4EB6-8516-4668-B494-E915A54E6916Q57115313-3178E8B2-C6E6-426C-93B3-C275A4EF9E2AQ57165886-99674DB8-8FC0-4431-9750-15AA89CE29C4Q57457356-60C3AD55-1E2B-466D-911C-606F93A770DFQ57805177-5496100B-EC5B-4612-9310-939F5E58D066Q58700518-83D44595-C429-4218-BB39-93E33D8544DAQ58800768-9506DD7B-9927-49F7-9FEC-5DA8D809BDCCQ86974750-B3ACA301-71CC-4345-BF34-CF30CB60C7ECQ88570163-CBD840B6-1F63-44D7-B17C-95B5BEB3A05AQ89408867-CFAD2477-C619-4D84-9559-01AD55556505Q89499241-391BDACE-E617-4A4F-B8F1-76D5898D8817Q89892309-B8336C7C-A72E-4EDF-A1F0-AFAD03386229Q89899787-37D153D2-0357-4F41-AE62-B205DF37EEC0Q90431507-B59A9CD9-9C24-46A2-9ABA-8D04CB7D0E04Q90438397-71F2FD70-E9F6-46E5-90A5-DF8A93D12D54Q90482568-31622B1C-6112-4FC7-827F-E4A44710C38BQ90548106-390B6A25-A736-442C-89ED-5E49E7CCAEDAQ90614437-07A578CD-B4A9-4C04-A4EB-B7657EB17B41Q90663870-E30E06CA-66A0-4538-953D-E5D0B6E5853AQ91073361-8FA8B560-BA7D-485C-AFE5-C5C5D86B3842Q91233884-1F7ED167-7FE2-43FB-A0D2-6935F1771352Q91393668-3F964E22-AD1D-4338-A99A-E4A410099251
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Volker M Lauschke
@es
Volker M Lauschke
@nl
Volker M Lauschke
@sl
Volker M. Lauschke
@en
type
label
Volker M Lauschke
@es
Volker M Lauschke
@nl
Volker M Lauschke
@sl
Volker M. Lauschke
@en
prefLabel
Volker M Lauschke
@es
Volker M Lauschke
@nl
Volker M Lauschke
@sl
Volker M. Lauschke
@en
P214
P1053
O-3014-2017
P106
P1153
56955751900
P21
P214
P2798
P31
P3829
P496
0000-0002-1140-6204
P569
2000-01-01T00:00:00Z
P735
P7859
viaf-305355298